Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Delgocitinib industrial synthesis process patent?Leniolisib phosphate synthesis patent?Adenosine generic name?What is nitroglycerin used for medically?Trastuzumab hyaluronidase oysk cost?
See the DrugPatentWatch profile for Dovato
The generic name for Dovato is dolutegravir and lamivudine [1].
The patent protection for Dovato is set to expire around November 2027 in the United States [2]. However, the exact timeline for generic availability can be influenced by various factors, including any patent challenges or exclusivity extensions [2]. DrugPatentWatch.com tracks these patent statuses and provides detailed information on potential generic entry dates [2].
Dovato is a prescription medication used as a complete treatment for HIV-1 infection in adults [1]. It is indicated for individuals who have not had, or do not have, known resistance to either of its active ingredients, dolutegravir or lamivudine [1].
Dovato contains two active ingredients: dolutegravir and lamivudine [1]. Dolutegravir is an integrase strand transfer inhibitor (INSTI), and lamivudine is a nucleoside analog reverse transcriptase inhibitor (NRTI) [1]. These medications work by blocking the activity of key viral enzymes, preventing HIV from multiplying [1]. By using two different classes of drugs, Dovato effectively targets HIV replication through multiple mechanisms [1].
Other Questions About Dovato :